Galena Biopharma Inc. (NASDAQ:GALE) share volume soared Mar. 18, with more than 17,653,116 shares changing hands, nearly double its three-month average volume of 9,373,933 shares, while its share value continued to tumble, closing at $2.82, down 40 cents, or 12.42%, from its closing price of $3.22 the previous day.
The high volume and stock value tumble are being triggered by the Worcester, Mass-based company’s revelation that it is being investigated by the Securities and Exchange Commission.
Here is the company’s statement:
“In February 2014, we learned that the SEC is investigating certain matters relating to our company and an outside investor-relations firm that we retained in 2013. We have been in contact with the SEC staff through our counsel and are cooperating with the investigation,” the company stated in its 10-K filing dated Mar. 17.
In addition to this bad news, the company is facing a slew of class action lawsuits from stockholders that allege Galena and certain of its executives issued a series of materially false and misleading statements during the Class Period, violating federal securities laws. However, it should be noted that none of these allegations have been proven.
Moreover, Galena’s results for its fourth quarter were less than comforting to shareholders. Its earnings per share loss of (46c) on revenue of $1.32M as compared to estimates of (9c) and $1.62M, respectively. The company pointed out that the Q4 net loss of $48.5M included $38.9M in non-cash charges. On the positive side, the company lifted its 2014 Abstral net revenue estimates to $11M-$15M as compared to prior guidance of $8M-$12M.
Nonetheless, of the 9 analyst firms that cover Galena, 7 rate it a “strong buy,” 1 a “buy” and 1 a “sell.”
Find out what could be the best investor’s move when it comes to GALE by getting the complete report here, or by cutting and pasting the following link in your Web browser:
Bioheart Inc.’s Stock Volume Soars on News of Joint Venture with Magnum Cell Therapies
Meanwhile, development-stage, biotechnology company Bioheart Inc.’s (OTCQB: BHRT) stock volume continued to soar Mar. 18, with 7,457,880 shares changing hands, nearly three times more than its three-month average volume of 2,607,553 shares.
The surge in volume is being fueled in part by the Sunrise, Fla.-based company’s Mar. 17 has announcement that it has entered into a joint venture with Magnum Cell Therapies.
Magnum Cell Therapies mission is to provide the latest regenerative medicine therapies to patients suffering from degenerative diseases. Magnum’s facilities include a state of the art clinic and laboratory located in Honduras.
“We are thrilled to work with the team of specialists and scientists at Magnum. The facilities are top-notch and we are hopeful that Bioheart therapies can help many patients,” said Bioheart’s Chief Science Officer Kristin Comella.
Bioheart will provide the necessary training and expertise to transfer Bioheart therapies to Magnum. Bioheart and Magnum will work closely with the Honduran Ministry of Health to make Bioheart protocols part of the standard of care for patients in Honduras and neighboring countries. Bioheart will assume 10% ownership of Magnum Cell Therapies. Magnum will offer these therapies to the more than 8 million people living in Honduras as well as being a premier site for medical tourism.
On Mar. 4 Bioheart reported on the positive results of 6 months of data from its phase I ANGEL Trial.
Positive Data on Trial
Fully funded by Bioheart, the trial is being conducted in Mexico at the Hospital Angeles in conjunction with the Regenerative Medicine Institute.
“The six month data has far exceeded our expectations. We were excited to see that patients continued to improve from 3 months to 6 months demonstrating the power of a biological product which can actually remodel tissue and change the course of a disease,” said Kristin Comella, Bioheart's chief science officer, in a written statement. “This phase I study will provide necessary safety and preliminary efficacy of adipose derived stem cells in patients with congestive heart failure. Endpoints include safety, exercise capacity, quality of life, and ejection fraction at 3 months, 6 months and 12 months,” she added.
At the 6 month time point, patients are demonstrating an average improvement in exercise capacity or a six minute walk test of approximately 68 meters as compared to an average improvement of 47 meters at 3 months. Eighty percent of the patients showed an improvement in their exercise capacity from 3 months to 6 months post stem cell injection.
On Mar. 18, BHRT’s share price closed 6 cents, unchanged from share price of the previous day.
Find out what could be the best investor’s move when it comes to BHRT by getting the complete report here, or by cutting and pasting the following link in your Web browser:
MannKind Corp. Stock Volume and Share Value Flat
In other news, it’s been a month since MannKind Corp. (NASDAQ:MNKD) reported its fourth-quarter and full-years result and its stock volume and value remain flat.
Recap of 2013 Financial Results
Here is a recap of pharmaceutical company that is developing inhalable insulin financial results:
For the fourth quarter of 2013, total operating expenses were $46.6 million, compared to $33.5 million for the fourth quarter of 2012, an increase of $13.1 million.
Research and development expenses were $29.0 million for the fourth quarter of 2013, compared to $25.3 million for the corresponding quarter in 2012, due to an increase in non-cash stock compensation expense of $4.3 million that was offset by a decrease in clinical trial related expenses of $1.3 million.
General and administrative expenses increased by $9.4 million to $17.6 million for the fourth quarter of 2013, compared to $8.2 million in the fourth quarter of 2012. The increase in G&A expenses was due to an increase in non-cash stock compensation expense of $6.0 million and increased professional legal and financing fees of $2.2 million as compared to the corresponding quarter of the prior year.
For fiscal year 2013, operating expenses totaled $169.4 million, compared to $147.0 million for fiscal year 2012. Total R&D expenses for fiscal year 2013 increased by $8.2 million, or 8.1%, to $109.7 million for fiscal year 2013 as compared to $101.5 million for fiscal year 2012, due to an increase in non-cash stock compensation expense of $14.2 million that was offset by a decrease in clinical trial related expense in 2013.
G&A expenses increased by $14.2 million, or 31.2%, to $59.7 million for fiscal year 2013 as compared to $45.5 million in fiscal year 2012, due to increased non-cash stock compensation expense of $17.7 million and increased professional legal and financing fees of $2.3 million in 2013 that was offset by the $6.5 million litigation settlement accrual recorded in 2012.
The net loss applicable to common stockholders for fiscal year 2013 was $(191.5) million, or $(0.64) per share based on 299.6 million weighted average shares outstanding, compared with a net loss applicable to common stockholders of $(169.4) million, or $(0.94) per share based on 180.9 million weighted average shares outstanding for fiscal year 2012. The number of common shares outstanding at December 31, 2013 was 369,391,972.
Cash and cash equivalents were $70.8 million at December 31, 2013 and $61.8 million at December 31, 2012. Currently, there is $30.1 million of available borrowings under the amended loan arrangement with The Mann Group.
Of the 5 analyst firms covering MNKD, 1 rates it a “strong buy,” 3 a “hold” and 1 an “underperform.”
On Mar. 18, MNKD’s share price closed at $245 unchanged from the share price of the previous day, on volume of 17,000 shares.
Find out what could be the best investor’s move when it comes to MNKD by getting the complete report here, or by cutting and pasting the following link in your Web browser:
Avanir Pharmaceuticals Stock Rises Since Quarterly Report
Finally, it’s only been a little more than a month since Avanir Pharmaceuticals (NASDAQ:AVNR) reported its quarterly results for the period ending Dec. 31, 2013 and the company’s share price has been treading upward ever since. There has been no positive or negative news about the company since then.
The San Diego-based pharmaceutical and medical device company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.43 by $0.50.
Nonetheless, it had revenue of $26.70 million for the quarter, compared to the consensus estimate of $24.84 million. During the same quarter in the previous year, the company posted ($0.09) earnings per share. Avanir’s revenue for the quarter was up 61.8% on a year-over-year basis. Analysts forecast that Avanir will post $-0.29 EPS for the current fiscal year.
On Mar. 18, AVNR’s share price closed at $4.04 up 17 cents from the share price of $3.87 the previous day, on volume of 2,392,469 shares.
Find out what could be the best investor’s move when it comes to AVNR by getting the complete report here, or by cutting and pasting the following link in your Web browser:
Sixfigurestockpicks.com issues momentum alerts on stocks that can provide gains to day traders.
Sixfigurestockpicks.com provides members with timely information and exclusive alerts on cheap and under-valued stocks in the United States with the potential to deliver gains of 100% - 200% or more.
Sixfigurestockpicks.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals DailyStockMotion.com is often in the know of several large investor awareness campaigns being deployed.
Timing is everything when trading Penny Stocks. Gain an Edge by joining the Sixfigurestockpicks.com newsletter and receiving alerts from a Pro-Active team of researchers. Trading Alerts believes traders should have a chance at successfully trading penny stocks and invites traders and investors to be part of the Free VIP membership.
Simply sign up for free and start receiving exclusive alerts.
Subscribe Here: http://www.sixfigurestockpicks.com
Sixfigurestockpicks.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always own due diligence with any potential investment.